WS #16402
Moderna shares plummeted 17% following the leak of phase 3 data for its personalized cancer vaccine, which failed to meet expectations. This follows a broader sell-off in small-cap biotech stocks like MGNX (-35%) and CATX (-25%) after disappointing clinical results. The sector is experiencing a 'sell-the-news' dynamic as investors rotate out of high-risk clinical-stage companies.
Healthcare Sector Volatility
Moderna shares plummeted 17% following the leak of phase 3 data for its personalized cancer vaccine, which failed to meet expectations. This follows a broader sell-off in small-cap biotech stocks like MGNX (-35%) and CATX (-25%) after disappointing clinical results. The sector is experiencing a 'sell-the-news' dynamic as investors rotate out of high-risk clinical-stage companies.